Logo

AbbVie's Qulipta (atogepant) Receives the US FDA's Approval for the Treatment of Migraine

Share this

AbbVie's Qulipta (atogepant) Receives the US FDA's Approval for the Treatment of Migraine

Shots:

  • The approval was based on a clinical program including P-III ADVANCE study- P-IIb/III study & P-III LTS study evaluated the safety- efficacy & tolerability of Qulipta (PO- 10/30/60mg) vs PBO in 2000 patients with EM who experienced 4-14 migraine days/mos.
  • The P-III ADVANCE & P-IIb/III study met its 1EPs i.e.- reduction in mean monthly migraine days @12wks. for all 3 doses. The 2EPs of the P-III trial showed that the proportion of patients achieved a 50-100% reduction in monthly migraine days (56%/59%/61% vs 29.0%) @12wks. & all doses were well tolerated in both studies
  • In the P-III study- patients treated with 60mg dose experienced a 4.2-day reduction from a baseline of 7.8 @12wks.

  | Ref: PR Newswire | Image: abbvie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions